Recruiting Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) NCT06112340 Conditions Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine System Diseases, +20 more Locations Bascom Palmer Eye Institute — Miami, Florida, United States West Virginia University Eye Institute — Morgantown, West Virginia, United States View Trial Details
Completed A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease NCT06226545 Conditions Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine System Diseases, +15 more Locations Site 111 — Beverly Hills, California, United States Site 105 — Palo Alto, California, United States Site 101 — San Diego, California, United States Site 103 — Miami, Florida, United States View all 15 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) NCT05276063 Conditions Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine System Diseases, +20 more Locations Thrive Health Research — Beverly Hills, California, United States UC San Diego Health — La Jolla, California, United States UCLA — Los Angeles, California, United States Byers Eye Institute - Stanford University — Palo Alto, California, United States View all 30 locations View more locations Show fewer locations Loading locations... View Trial Details
